Matricelf is a pioneering biotechnology company developing a platform for autologous matrix and cells implants for a wide range of medical conditions. The company was established in 2019 by Professor Tal Dvir of the Laboratory for Tissue Engineering and Regenerative Medicine from Tel Aviv University. Our patented technology is a product of eight years of research and $12 million in grants.
European Patent Office officially grants patent titled “PARTICLES COMPRISING DECELLULARIZED OMENTUM” for the production of micro-implants for the treatment of a variety of diseases and tissue injuries
Matricelf (TASE:MTLF) announced today that scientists from Sagol Center for Regenerative Biotechnology at Tel Aviv University have engineered 3D spinal cord tissues and implanted them in mice model with long-term chronic paralysis.
Matricelf is happy to announce that it has completed and signed an exclusive, global, license agreement with Ramot, the technology transfer arm of Tel Aviv University for the development and commercialization of a novel technology in 3D bioprinting of tissues and organs.
We are pleased to announce that we completed another successful usability study with our human implants to bridge spinal cord injury in a live porcine.
